Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00813332
Other study ID # simcere002
Secondary ID simcere0802
Status Recruiting
Phase Phase 4
First received December 19, 2008
Last updated January 22, 2010
Start date October 2008
Est. completion date October 2010

Study information

Verified date December 2009
Source Simcere Pharmaceutical Co., Ltd
Contact Kai LI, Professor
Phone 0086-22-81351613
Email likai5@medmail.com.cn, likqupp@yahoo.com
Is FDA regulated No
Health authority China: Food and Drug AdministrationUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the efficacy and safety of Endostar (Recombinant Human Endostatin) combined with Docetaxel and single Docetaxel through multi-center, double-blinding, randomized controlled, phase Ⅳ clinical trial for NSCLC cases who have obvious progressive disease or intolerant adverse effects in first-line chemotherapy.


Description:

The combinative therapy of Endostar, Vinorelbine and cisplatin has been shown to increase response rate and survival in patients (pts) with advanced NSCLC and is sFDA-approved for this indication. However, there are limited data on the safety and efficacy of Endostar in combination with other widely used chemotherapy doublets for NSCLC. Clinical data proved that Endostar was a wild spectrum and safe antiangiogenesis factor which could suppress almost 65 kinds of tumor mass in animal models and affect about 12 percent human genome. In this clinical trial, there will be 160 patients enrollment, giving Docetaxel (75mg/m2,iv, d1, every 3 weeks) plus Endostar(7.5mg/m2/day, iv, d1-d14, every 3 weeks) or Docetaxel with placebo. We'll evaluate the efficacy and safety of the Docetaxel plus Endostar treatment to NSCLC and hope to provide a promising regimen to advanced lung cancer patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date October 2010
Est. primary completion date October 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Age 18-75 years old, males or females;

2. Patients with NSCLC confirmed by histopathology or cytology who need second-line chemotherapy, including progressive disease cases during or in 3 months posterior to end of first-line chemotherapy( at least 4 cycles done) and cases with intolerant adverse effects in first-line chemotherapy( at least 4 cycles done); neo-adjuvant chemotherapy and targeted therapy(EFGR-TKIs) not to be served as first-line chemotherapy; 3 months of clearance needed for neo-adjuvant chemotherapy and 1 month for targeted and first-line chemotherapy;

3. Local advanced and metastatic cases with tumor foci that can be evaluated by CT, MRI or PET-CT; at least one diameter = 1 cm (including metastatic lymph nodes) confirmed by CT scan or = 1 cm by spin CT or PET-CT );

4. No contraindication for chemotherapy, with normal peripheral hemogram, renal and hepatic function: Peripheral hemogram: WBC=4.0×109/L,PLT=80×109/L,Hgb=90g/L; Renal function: serum BUN and creatinine =1.0×UNL; Hepatic function: transaminase=1.5×UNL, BIL=×UNL;

5. Karnofsky performance scale=60 or ECOG performance scale= 2; expected survival time=3 months;

6. No allergic history to biological agents and taxane agents;

7. Patients are voluntary to participate and sign the informed contents.

Exclusion Criteria:

1. Pregnant or breast-feeding females; or females who have reproductive ability but do not take contraception method;

2. With severe acute infection uncontrolled; purulent or chronic infection with wounds difficult to recover;

3. With history of severe heart diseases, including congestive heart failure, uncontrolled arrhythmia with high risk, unstable angina pectoris, myocardial infarction, severe cardiac valvular diseases and refractory hypertension;

4. Patients with uncontrolled neurological, mental disease or psychosis, patients with poor compliance that cannot coordinate the therapy or describe the treatment response;

5. Uncontrolled brain metastasis patients with obvious manifestations of intracranial hypertension or neurological and mental disorders;

6. Uncontrolled diabetes and contraindication to corticoid agents;

7. Obvious hemorrhage tendency;

8. Allergic to any drug in the trial;

9. Patients with a second tumor;

10. Patients participating in other clinical trials;

11. Patients treated by Endostar or Docetaxel (excluding neo-chemotherapy) included combination chemotherapy previously;

12. Foci to be evaluated for response in trial treated by radiation in 6 months.

13. Other conditions that are regarded for exclusion by the trialists.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Intervention

Drug:
Endostar(rh recombinant endostatin) plus Docetaxel
7.5mg/m2, IV( in the vein) on day1-14 of each 21-28 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
Placebo plus Docetaxel
Placebo plus Docetaxel

Locations

Country Name City State
China Cancer Hospital of Tianjin Medical University Tianjin

Sponsors (1)

Lead Sponsor Collaborator
Simcere Pharmaceutical Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival time,survival rate for 1 year two years (2010.10) No
Secondary Tumor response rate, disease controlled rate and adverse effects. 1 year (2009.10) Yes
See also
  Status Clinical Trial Phase
Recruiting NCT02133196 - T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Phase 2
Completed NCT03215810 - Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Phase 1
Recruiting NCT04982224 - Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer Phase 1/Phase 2
Recruiting NCT05609578 - Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation Phase 2
Not yet recruiting NCT04992858 - Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations Phase 2
Active, not recruiting NCT03127449 - AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations N/A
Not yet recruiting NCT06356675 - A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy Phase 4
Completed NCT03074175 - Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer:Multicenter Controlled Study.(RadmiR-01) N/A
Terminated NCT05106335 - A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC Phase 3
Not yet recruiting NCT04229121 - Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
Completed NCT05219162 - Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). Phase 4
Not yet recruiting NCT05859217 - A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) Phase 2
Recruiting NCT03062800 - Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003) Phase 2
Completed NCT02055508 - POSITIVE - Study (Part III) Heidelberg N/A
Active, not recruiting NCT04043195 - Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC Phase 1/Phase 2